132 related articles for article (PubMed ID: 35431121)
1. Effect of Race and Ethnicity on Risk of Radiotherapy Toxicity and Implications for Radiogenomics.
Abdelkarem OAI; Choudhury A; Burnet NG; Summersgill HR; West CML
Clin Oncol (R Coll Radiol); 2022 Oct; 34(10):653-669. PubMed ID: 35431121
[TBL] [Abstract][Full Text] [Related]
2. Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
Matta R; Chapple CR; Fisch M; Heidenreich A; Herschorn S; Kodama RT; Koontz BF; Murphy DG; Nguyen PL; Nam RK
Eur Urol; 2019 Mar; 75(3):464-476. PubMed ID: 30573316
[TBL] [Abstract][Full Text] [Related]
3. Independent validation of genes and polymorphisms reported to be associated with radiation toxicity: a prospective analysis study.
Barnett GC; Coles CE; Elliott RM; Baynes C; Luccarini C; Conroy D; Wilkinson JS; Tyrer J; Misra V; Platte R; Gulliford SL; Sydes MR; Hall E; Bentzen SM; Dearnaley DP; Burnet NG; Pharoah PD; Dunning AM; West CM
Lancet Oncol; 2012 Jan; 13(1):65-77. PubMed ID: 22169268
[TBL] [Abstract][Full Text] [Related]
4. Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.
Andreassen CN; Rosenstein BS; Kerns SL; Ostrer H; De Ruysscher D; Cesaretti JA; Barnett GC; Dunning AM; Dorling L; West CML; Burnet NG; Elliott R; Coles C; Hall E; Fachal L; Vega A; Gómez-Caamaño A; Talbot CJ; Symonds RP; De Ruyck K; Thierens H; Ost P; Chang-Claude J; Seibold P; Popanda O; Overgaard M; Dearnaley D; Sydes MR; Azria D; Koch CA; Parliament M; Blackshaw M; Sia M; Fuentes-Raspall MJ; Ramon Y Cajal T; Barnadas A; Vesprini D; Gutiérrez-Enríquez S; Mollà M; Díez O; Yarnold JR; Overgaard J; Bentzen SM; Alsner J;
Radiother Oncol; 2016 Dec; 121(3):431-439. PubMed ID: 27443449
[TBL] [Abstract][Full Text] [Related]
5. Volumetric-Modulated Arc Radiotherapy with Daily Image-Guidance Carries Better Toxicity Profile for Higher Risk Prostate Cancer.
Ghanem AI; Elsaid AA; Elshaikh MA; Khedr GA
Asian Pac J Cancer Prev; 2021 Jan; 22(1):61-68. PubMed ID: 33507680
[TBL] [Abstract][Full Text] [Related]
6. Finding the genetic determinants of adverse reactions to radiotherapy.
Rattay T; Talbot CJ
Clin Oncol (R Coll Radiol); 2014 May; 26(5):301-8. PubMed ID: 24702740
[TBL] [Abstract][Full Text] [Related]
7. Rectal/urinary toxicity after hypofractionated vs conventional radiotherapy in low/intermediate risk localized prostate cancer: systematic review and meta analysis.
Di Franco R; Borzillo V; Ravo V; Ametrano G; Falivene S; Cammarota F; Rossetti S; Romano FJ; D'Aniello C; Cavaliere C; Iovane G; Piscitelli R; Berretta M; Muto P; Facchini G
Oncotarget; 2017 Mar; 8(10):17383-17395. PubMed ID: 28129649
[TBL] [Abstract][Full Text] [Related]
8. A genome wide association study (GWAS) providing evidence of an association between common genetic variants and late radiotherapy toxicity.
Barnett GC; Thompson D; Fachal L; Kerns S; Talbot C; Elliott RM; Dorling L; Coles CE; Dearnaley DP; Rosenstein BS; Vega A; Symonds P; Yarnold J; Baynes C; Michailidou K; Dennis J; Tyrer JP; Wilkinson JS; Gómez-Caamaño A; Tanteles GA; Platte R; Mayes R; Conroy D; Maranian M; Luccarini C; Gulliford SL; Sydes MR; Hall E; Haviland J; Misra V; Titley J; Bentzen SM; Pharoah PD; Burnet NG; Dunning AM; West CM
Radiother Oncol; 2014 May; 111(2):178-85. PubMed ID: 24785509
[TBL] [Abstract][Full Text] [Related]
9. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities.
Würnschimmel C; Wenzel M; Collà Ruvolo C; Nocera L; Tian Z; Saad F; Briganti A; Shariat SF; Mandel P; Chun FKH; Tilki D; Graefen M; Karakiewicz PI
World J Urol; 2021 Oct; 39(10):3781-3787. PubMed ID: 33978812
[TBL] [Abstract][Full Text] [Related]
10. The impact of race on survival in metastatic prostate cancer: a systematic literature review.
Freedland SJ; Samjoo IA; Rosta E; Lansing A; Worthington E; Niyazov A; Nazari J; Arondekar B
Prostate Cancer Prostatic Dis; 2023 Sep; 26(3):461-474. PubMed ID: 37592001
[TBL] [Abstract][Full Text] [Related]
11. Is Our Science Representative? A Systematic Review of Racial and Ethnic Diversity in Orthopaedic Clinical Trials from 2000 to 2020.
Cwalina TB; Jella TK; Manyak GA; Kuo A; Kamath AF
Clin Orthop Relat Res; 2022 May; 480(5):848-858. PubMed ID: 34855650
[TBL] [Abstract][Full Text] [Related]
12. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
Zelefsky MJ; Levin EJ; Hunt M; Yamada Y; Shippy AM; Jackson A; Amols HI
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(4):1124-9. PubMed ID: 18313526
[TBL] [Abstract][Full Text] [Related]
13. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. A Systematic Review of Patient Race, Ethnicity, Socioeconomic Status, and Educational Attainment in Prostate Cancer Treatment Randomised Trials-Is the Evidence Base Applicable to the General Patient Population?
Patki S; Aquilina J; Thorne R; Aristidou I; Rodrigues FB; Warren H; Bex A; Kasivisvanathan V; Moore C; Gurusamy K; Emberton M; Best LMJ; Tran MGB
Eur Urol Open Sci; 2023 Aug; 54():56-64. PubMed ID: 37545851
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated radiotherapy for the treatment of prostate cancer: a systematic review and economic evaluation.
Hummel S; Simpson EL; Hemingway P; Stevenson MD; Rees A
Health Technol Assess; 2010 Oct; 14(47):1-108, iii-iv. PubMed ID: 21029717
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity.
Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Thomas G; Kiss A; Mamedov A; Deabreu A
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):898-905. PubMed ID: 21237581
[TBL] [Abstract][Full Text] [Related]
18. Is there an increase in genitourinary toxicity in patients treated with transurethral resection of the prostate and radiotherapy? A systematic review.
Ishiyama H; Hirayama T; Jhaveri P; Satoh T; Paulino AC; Xu B; Butler EB; Teh BS
Am J Clin Oncol; 2014 Jun; 37(3):297-304. PubMed ID: 22706173
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of Genome Wide Association Studies Identifies Genetic Markers of Late Toxicity Following Radiotherapy for Prostate Cancer.
Kerns SL; Dorling L; Fachal L; Bentzen S; Pharoah PD; Barnes DR; Gómez-Caamaño A; Carballo AM; Dearnaley DP; Peleteiro P; Gulliford SL; Hall E; Michailidou K; Carracedo Á; Sia M; Stock R; Stone NN; Sydes MR; Tyrer JP; Ahmed S; Parliament M; Ostrer H; Rosenstein BS; Vega A; Burnet NG; Dunning AM; Barnett GC; West CM;
EBioMedicine; 2016 Aug; 10():150-63. PubMed ID: 27515689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
